Springworks Therapeutics Intrinsic Value – ProShare Advisors LLC Increases Investment in SpringWorks Therapeutics,
May 6, 2023
Trending News 🌥️
SPRINGWORKS ($NASDAQ:SWTX): ProShare Advisors LLC, a financial services company, has recently increased its holdings in SpringWorks Therapeutics, Inc., a biopharmaceutical company focused on developing life-altering therapies for patients with serious rare and cancer diseases. SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for serious rare and cancer diseases. Their team of experienced professionals leverages novel insights and cutting-edge technologies to develop pioneering treatments and provide hope to patients and their families.
The company has a strong focus on cancer biology and is developing innovative therapies to target specific pathways involved in cancer progression. SpringWorks Therapeutics also works with other leading biopharmaceutical companies to develop next-generation treatments and explore potential partnerships.
Share Price
ProShare Advisors LLC recently increased its investment in SpringWorks Therapeutics, Inc. (SPRINGWORKS). On Thursday, SPRINGWORKS stock opened at $24.2 and closed the day at $23.6, which was a 2.2% decrease from the previous closing price of $24.2. This downswing may have been influenced by the announcement of ProShare Advisors LLC increasing its investment in SpringWorks Therapeutics, Inc. Despite the slight fall in stock prices, the company is likely to benefit from ProShare Advisors LLC’s increased investment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Springworks Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -289.04 | -130.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Springworks Therapeutics. More…
| Operations | Investing | Financing |
| -174.69 | -143.42 | 338.59 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Springworks Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 569.2 | 62.27 | 8.11 |
Key Ratios Snapshot
Some of the financial key ratios for Springworks Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -132.4% |
| FCF Margin | ROE | ROA |
| -93.8% | -34.8% | -32.6% |
Analysis – Springworks Therapeutics Intrinsic Value
At GoodWhale, we have been closely analyzing the fundamentals of SPRINGWORKS THERAPEUTICS. Through our proprietary Valuation Line, we have determined the intrinsic value of a SPRINGWORKS THERAPEUTICS share to be around $46.5. This means that the current market value of SPRINGWORKS THERAPEUTICS, which is $23.6, is significantly undervalued by 49.2%. This presents a great opportunity for investors to purchase SPRINGWORKS THERAPEUTICS at a discounted rate. More…
Peers
The company is focused on developing and commercializing therapies for the treatment of rare and underserved diseases. SpringWorks Therapeutics Inc’s competitors include Aadi Bioscience Inc, Avalo Therapeutics Inc, and Immunic Inc.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s lead product candidate is AB-101, a small molecule inhibitor of the PI3K/mTOR pathway, which is in Phase I clinical trials for the treatment of solid tumors. Aadi Bioscience Inc has a market cap of 317.87M as of 2022, a Return on Equity of -28.05%.
– Avalo Therapeutics Inc ($NASDAQ:AVTX)
Avalo Therapeutics Inc is a clinical stage biopharmaceutical company developing novel cancer therapies. The company’s market cap as of 2022 is 50.93M and its ROE is 729.23%. Avalo’s pipeline of products includes two clinical stage programs: AVL-292, a first-in-class, small molecule inhibitor of checkpoint kinase 1 (Chk1) for the treatment of solid tumors, and AVL-181, a first-in-class, small molecule inhibitor of checkpoint kinase 2 (Chk2) for the treatment of hematologic malignancies.
– Immunic Inc ($NASDAQ:IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing oral therapies for the treatment of immune-mediated diseases. Its pipeline includes IMU-838 that is in Phase II clinical trial for the treatment of plaque psoriasis and atopic dermatitis; and IMU-935, which is in Phase I clinical trial for the treatment of autoimmune diseases. The company was founded by Daniel M. Adelman, Michael J. Brenner and William T. Symonds on December 15, 2006 and is headquartered in New York, NY.
Summary
ProShare Advisors LLC recently increased its stake in SpringWorks Therapeutics, Inc. (SPRINGWORKS), an oncology-focused biopharmaceutical company. SPRINGWORKS is a leader in developing potential treatments for people with rare and life-threatening cancers, and the investment is reflective of the potential the company has for growth. ProShare’s involvement also offers SPRINGWORKS exposure to a wider range of investors and potential partners. SpringWorks has a portfolio of small molecule, biologic, and immuno-oncology therapies, with plans to develop more treatments and expand its pipeline.
Its lead product candidate is currently in Phase 3 clinical trials in the United States and Europe. Furthermore, the company has multiple strategic partnerships with other leading biopharmaceutical companies. As SPRINGWORKS continues to advance its development programs and strengthen its financial position, it is likely to draw more interest from investors.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
